Core Viewpoint - Green Kang Biochemical has completed the transfer of its controlling shareholder from Shanghai Kangyi to Zongteng Network, alongside the divestiture of its photovoltaic assets, amidst ongoing financial struggles and operational challenges in its core veterinary medicine business [1][3]. Group 1: Company Background and Financial Struggles - Green Kang Biochemical, originally focused on veterinary drug R&D and production, has faced declining net profits since its IPO in 2017, culminating in significant losses starting in 2021 [1][2]. - The company reported a total loss of 789 million yuan from 2022 to 2024, with its net assets reaching -24.54 million yuan by the end of 2024, leading to a risk of delisting [3][4]. Group 2: Transition to Photovoltaic Business - The company attempted to pivot to the photovoltaic sector by acquiring Jiangxi Weike New Materials Technology Co., with a premium of 632%, but this transition resulted in substantial losses due to falling prices in the photovoltaic industry [2][3]. - The photovoltaic business accounted for approximately 36% of the company's revenue in 2024, but the overall revenue from the veterinary business remains critical, constituting 84% of the adjusted revenue [5][6]. Group 3: New Controlling Shareholder and Future Prospects - Zongteng Network, the new controlling shareholder, specializes in cross-border logistics and reported a revenue of 27.105 billion yuan and a net profit of 1.122 billion yuan in 2024, raising questions about its ability to turn around Green Kang Biochemical's fortunes [6]. - The veterinary business has shown volatility, with a gross margin of only 7.35% in 2024, although it improved to 21.61% in the first half of the year due to rising pig prices [5][6].

Group 1 - The core viewpoint of the articles highlights the financial struggles and ongoing restructuring efforts of Gansu King Kong Photovoltaic Co., Ltd. (*ST King Kong) as it faces significant losses despite revenue growth [1][2] Group 2 - In the first half of 2025, *ST King Kong reported operating revenue of 140 million yuan, a year-on-year increase of 169.02%, but the net profit attributable to shareholders was -282 million yuan, worsening from -223 million yuan in the same period last year [1] - The increase in revenue is attributed to the company's active expansion into overseas sales [1] - The company has experienced continuous losses from 2021 to 2024, with losses of 202 million yuan, 269 million yuan, 362 million yuan, and 795 million yuan respectively [1] Group 3 - *ST King Kong is currently undergoing pre-restructuring and restructuring procedures, initiated by creditors due to the company's inability to repay due debts [2] - Guangdong Ouhao Group Co., Ltd. has been identified as the industrial investor to lead the restructuring efforts in collaboration with Shanghai Hongqi Yunchuang Technology Group Co., Ltd. [2] - On August 8, 2025, *ST King Kong signed a financial investment agreement with 16 restructuring financial investors, who will collectively pay 1.41975 billion yuan at a price of 7.5 yuan per share to assist in debt repayment and production recovery [2] Group 4 - Following the restructuring funds' arrival, *ST King Kong plans to initiate a capital reserve transfer to increase share capital and transfer shares to the investors' accounts [2] - The company aims to complete the stock transfer by December 31, 2025, or no later than the disclosure of the 2025 annual report [2] - In June 2025, *ST King Kong established Beijing King Kong Shuhai Intelligent Computing Technology Co., Ltd. to engage in computing-related businesses and signed a service agreement worth approximately 399 million yuan for high-performance computing services [2]